CRISPR Therapies, Base Editing and Approvals — 2026-10-03
A breakthrough CRISPR therapy for difficult-to-treat cholesterol disorders cut LDL and triglycerides by roughly half in a first-in-human trial, with benefits sustained one year later. Meanwhile, CRISPR Therapeutics faces intensifying competition from peers as multiple late-stage programs converge toward 2026 readouts, while Intellia's lead CRISPR drug for hereditary angioedema advances toward FDA review with a March 2027 decision date.
CRISPR Therapies, Base Editing and Approvals — 2026-10-03
Top developments
CRISPR therapy durably slashes cholesterol in lipid disorder patients
A single infusion of an experimental CRISPR-Cas9 therapy cut LDL cholesterol by 52.5% and triglycerides by 47.8% in patients with medication-resistant lipid disorders, with reductions still present one year later. This represents one of the most sustained efficacy signals for in vivo CRISPR editing in a difficult-to-treat population and suggests genome editing can produce durable therapeutic benefit in a single dosing regimen.
Prime Medicine wins FDA clearance for Alpha-1 antitrypsin deficiency trial
Prime Medicine received FDA clearance to initiate clinical testing of PM647, an investigational in vivo prime editor targeting Alpha-1 Antitrypsin Deficiency (AATD). The clearance enables Prime to begin human studies for a condition affecting roughly 100,000 individuals in the U.S. and an estimated 200,000 across the US and Europe. The move positions prime editing—a next-generation variant of CRISPR that makes precise edits without creating double-strand DNA breaks—as a direct clinical competitor to Beam Therapeutics' base-editing approach for the same disease.
Intellia advances first in vivo CRISPR drug toward FDA review
Intellia Therapeutics announced FDA acceptance of its biologics license application for lonvoguran ziclumeran (lonvo-z), its in vivo CRISPR therapy for hereditary angioedema, with priority review granted. The FDA set a PDUFA target action date of March 10, 2027. If approved, lonvo-z would be the world's first in vivo CRISPR-based therapy and the only one-time treatment for hereditary angioedema, positioning Intellia ahead of competitors in converting CRISPR from research into marketed medicine.
CRISPR Therapeutics faces peer competition pressure ahead of 2026 catalysts
CRISPR Therapeutics is approaching two pivotal near-term catalysts by year-end 2026, but analysts caution the company will be judged against results from competitors entering late-stage development simultaneously. Lilly's VERVE-102 in vivo program has already treated 35 patients and is expected to enter Phase 2 by late 2026, while Prime and CRISPR Therapeutics remain in dose-finding studies with no human data yet released. This convergence of programs means competitive advantage will depend on speed of advancement and durability of efficacy data.
Context & numbers
Pricing and payer models: Casgevy (exagamglogene autotemcel), Vertex's approved CRISPR-based sickle cell therapy, lists at $2.2 million, while Bluebird Bio's Lyfgenia lists at $3.1 million. By March 2026, 33 U.S. states plus DC had enrolled in CMS's Cell and Gene Therapy Access Model, representing approximately 84% of the Medicaid sickle cell population, under which manufacturers refund portions of the price if patients miss defined clinical benchmarks—the first multi-state, federally negotiated outcomes-based agreement for any gene therapy.
Clinical population: AATD affects an estimated 100,000 individuals in the U.S. and 200,000 across the US and Europe, with the PiZZ genotype—Prime's target—present in this population.
On the radar
- Intellia's PDUFA decision: March 10, 2027 is the FDA target action date for lonvo-z; approval would mark the first marketed in vivo CRISPR therapy globally and a major inflection point for the field.
- Late-2026 competitive readouts: CRISPR Therapeutics, Lilly (VERVE-102 Phase 2 entry), and other in vivo programs are converging on major data releases and advancement milestones before year-end; outcomes will determine market leadership.
- Base vs. prime editing rivalry: Beam Therapeutics' base-editing program for AATD (BEAM-302) reported Phase 1/2 data targeting accelerated FDA approval, while Prime's prime-editing alternative just gained clearance to begin trials—direct head-to-head competition in the same indication is now underway.
[Source citations verified: all data published or updated between 2026-09-26 and 2026-10-03]
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
